`571-272-7822
`
` Paper 29
` Entered: July 31, 2019
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`AMNEAL PHARMACEUTICALS LLC,
`Petitioner,
`
`v.
`
`ALKERMES PHARMA IRELAND LIMITED,
`Patent Owner.
`____________
`
`Case IPR2018-00943
`Patent 7,919,499 B2
`____________
`
`Before CHRISTOPHER M. KAISER, JACQUELINE T. HARLOW, and
`KRISTI L. R. SAWERT, Administrative Patent Judges.
`
`SAWERT, Administrative Patent Judge.
`
`DECISION
`Granting Joint Motion to Terminate
`35 U.S.C. § 317(a) and 37 C.F.R. § 42.74
`
`APOTEX EXHIBIT 1059
`Apotex v. Alkermes
`IPR2025-00514
`
`
`
`IPR2018-00943
`Patent 7,919,499 B2
`
`
`
`
`
`On July 30, 2019, pursuant to the Board’s authorization, Amneal
`Pharmaceuticals LLC (“Petitioner”) and Alkermes Pharma Ireland Limited
`(“Patent Owner”) filed a joint motion to terminate this inter partes review
`pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. § 42.74. Paper 27 (“Motion”
`or “Mot.”). The motion was accompanied by a true, unredacted copy of a
`Settlement and License Agreement (Ex. 2058), and a joint request to treat
`the Settlement and License Agreement as business confidential information,
`to be kept separate from the patent file, pursuant to 35 U.S.C. § 317(b) and
`37 C.F.R. § 42.74(c) (Paper 28).
`The parties represent in their joint motion that they “have settled their
`disputes” and have “executed a Settlement and License Agreement that
`authorizes the Parties to seek termination of this inter partes review.”
`Mot. 2. Additionally, the parties state that the patent-at-issue in this
`proceeding, U.S. Patent No. 7,919,499 B2 (“the ’499 patent”), is not
`involved in any related district court litigations, or in any related inter partes
`review proceedings. Id.
`The Board generally expects that a case “will terminate after the filing
`of a settlement agreement, unless the Board has already decided the merits.”
`Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,768 (Aug. 14,
`2012); see also 37 C.F.R. § 42.72. Here, although the Board has instituted
`an inter partes review of claims 1–13 of the ’499 patent, the Board has not
`heard oral argument and has not decided the merits of the proceeding.
`Under the circumstances presented here, therefore, we determine that
`it is appropriate to terminate this proceeding with respect to both Petitioner
`and Patent Owner. Accordingly, we grant the parties’ joint motion to
`terminate.
`
`
`
`2
`
`
`
`IPR2018-00943
`Patent 7,919,499 B2
`
`
`
`
`
`We also determine that the parties have complied with the
`requirements of 37 C.F.R. § 42.74(c) to have the Settlement and License
`Agreement treated as business confidential information and kept separate
`from the files of the patent-at-issue in this proceeding. Thus, we grant the
`joint request to treat the Settlement and License Agreement as business
`confidential.
`Accordingly, it is
`ORDERED that the joint motion to terminate the proceeding is
`GRANTED;
`FURTHER ORDERED that the joint request to treat the parties’
`Settlement and License Agreement as business confidential information, to
`be kept separate from the patent file, is GRANTED; and
`FURTHER ORDERED that the instant proceeding is TERMINATED.
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`IPR2018-00943
`Patent 7,919,499 B2
`
`FOR PETITIONER:
`Tedd W. Van Buskirk
`Michael H. Teschner
`Kendall K. Gurule
`LERNER, DAVID, LITTENBERG,
`KRUMHOLZ & MENTLIK, LLP
`litigation@lernerdavid.com
`tvanbuskirk@lernerdavid.com
`mteschner.ipr@ldlkm.com
`kgurule@lernerdavid.com
`
`FOR PATENT OWNER:
`
`Naveen Modi
`Bruce M. Wexler
`Michael Stramiello
`Joseph M. O’Malley Jr.
`Gerard A. Salvatore
`PAUL HASTINGS LLP
`PH-Amneal-Alkermes-IPR@paulhastings .com
`naveenmodi@paulhastings.com
`brucewexler@paulhastings.com
`michaelstramiello@paulhastings.com
`josephomalley@paulhastings.com
`gerardsalvatore@paulhastings.com
`
`
`
`
`
`
`
`
`
`
`
`4
`
`